ArticleBiochemistry and biophysics reports2025
Altered lipidomic and metabolomic status in cerebrospinal fluid of children with myelin oligodendrocyte glycoprotein antibody-associated disorder.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebrospinal fluid metabolomic signatures in paediatric MOGAD and POMS.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a group of acquired demyelinating syndromes affecting the central nervous system. MOGAD-associated bioactive molecules remain elusive. A retrospective case-control study was performed to characterize the biochemical and immunological profiles of cerebrospinal fluid (CSF) in MOGAD. Thirteen patients with MOGAD (onset age: 2-14 years, 6 females) and five patients with epilepsy, serving as controls, were enrolled. Liquid chromatography with tandem mass spectrometry was used for lipidomic and metabolomic analyses using CSF samples collected at disease onset (n = 5). The MS/MS system detected a total of 7527 molecules in lipidomic and 17,526 molecules in metabolomic analyses of CSF. Among them, 162 (0.02 %) lipophilic molecules were detected at levels that differed from those of controls. Among the 549 (0.03 %) hydrophilic molecules that were differentially presented, pyridoxine, ribitol, and isethionate levels were significantly lower in patients with MOGAD. Both lipidomic and metabolomic analyses, discriminated CSF samples of patients with MOGAD from controls using Uniform Manifold Approximation and Projection. In summary, CSF samples from children with MOGAD exhibit distinctive lipidomic and metabolomic profiles. These findings provide evidence for the diagnostic potential of CSF-based lipidomic and metabolomic analyses for childhood-onset MOGAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.